hypogonadism%20in%20males%20-%20late-onset
HYPOGONADISM IN MALES - LATE-ONSET
Late onset hypogonadism is defined as clinical and biochemical syndrome characterized by older age, set of typical symptoms, and deficiency in serum testosterone levels.
The quality of life may be decreased and multiple organ systems may be adversely affected.
Prior to the start of testosterone substitution, there should be confirmation of low serum testosterone and a confirmation of need based on clinical findings.
Only if the potential benefit exceeds the risk, then replacement testosterone should be started.

Introduction

  • A type of hypogonadism that has normal pubertal development thus w/ developed normal male secondary sex characteristics
  • Prevalence of hypogonadism increases w/ age
  • Quality of life may be decreased
  • Multiple organ systems may be adversely affected

Definition

  • Late-onset hypogonadism (LOH) is defined as a clinical & biochemical syndrome caused by androgen deficiency characterized by:
    • Older age
    • Set of typical symptoms
    • Deficiency in serum testosterone levels

Signs and Symptoms

  • Decreased sexual desire & erectile quality & frequency; especially nocturnal erections
  • Mood changes, including:
    • Decreases in intellectual activity, cognitive function, spatial orientation ability
    • Fatigue
    • Depression
    • Irritability 
  • Sleep disturbances
  • Decrease in lean body mass w/ decrease in muscle volume & strength
  • Increase in visceral fat
  • Decrease in body hair & skin alterations
  • Osteopenia, osteoporosis & increased risk of bone fractures may develop from a decrease in bone mineral density
  • Hot flushes
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.